Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.

Neurooncol Adv · 2024 · PMC11632829 · PMID 39664679

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally nonsignificantno p-value reported

However, even though the difference was marginally nonsignificant, it suggests a trend where larger extents of resection may be associated with lower progression rates.

also in 149 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.